Skip to main content

Maria Luisa Aznar Ruiz de Alegria

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca
Infectious Diseases
General Hospital
Maria Luisa Aznar Ruiz de Alegria

Maria Luisa Aznar Ruiz de Alegria

Maria Luisa Aznar Ruiz de Alegria

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca
Infectious Diseases
General Hospital

Projects

Malalties infeccioses

IP: Vicenç Falcó Ferrer
Collaborators: Jose Santos Santiago, Maria Luisa Aznar Ruiz de Alegria, Adria Curran Fàbregas, Jorge Nestor Garcia Perez, Oscar Len Abad, Mª Carmen Ferrer Barberà, Javier Gomis Rodriguez, Diana Pou Ciruelo, Begoña Treviño Maruri, Nuria Fernández Hidalgo, Joan Gavaldà Santapau, Juan Espinosa Pereiro, Bibiana Planas Ribas, Ma Dolores Rodríguez Pardo, Pau Bosch Nicolau, David Perea Pérez, Israel Molina Romero, Patricia Álvarez López, Luis Lopez Perez, Vicente Descalzo Jorro, Marta Sanchiz Cruz, Nuria Serre Delcor, Laura Escola Verge, Julia Sellares Nadal, Fernando M Salvador Velez, Isabel Ruiz Camps, Estela Muñoz Castarlenas, Marta Palau Gauthier, Jordi Gómez i Prat, María José Buzón Gómez, Hakima Ouaarab Essadek, Paula Suanzes Diez, Jordi Navarro Mercadé, Esperanza Esteban Serna, Raisa Morales Martinez, Joaquin Burgos Cibrian, Nerea Sanchez Gaona, Joan Rey Cano, Adrián Sánchez Montalvá, Cristina Mancebo Perez, Montserrat Llinás Vidal, Sebastian Gonzalez Kuguel, Ana Gallego Cortes, Maider Arando Lasagabaster, Ibai Los Arcos Bertiz, Claudia Broto Cortes, Ester Marquez Algaba, Benito Almirante Gragera, Desideria Martinez Rascón, Lucia Rodriguez Vazquez, Meritxell Genesca Ferrer, Ines Mercedes Oliveira Souto, Silvina Andrea Magnani , Yasmine Margaret Baktash , Daniël Kees Johan Pieren
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 60000
Reference: 2021 SGR 00764
Duration: 01/01/2022 - 31/12/2024

Enfermedades infecciosas

IP: Israel Molina Romero
Collaborators: Maria Luisa Aznar Ruiz de Alegria, Eva Baldrich Rubio, Diana Pou Ciruelo, Begoña Treviño Maruri, Pau Bosch Nicolau, Nuria Serre Delcor, Fernando M Salvador Velez, Mª Teresa Tórtola Fernández, Adrián Sánchez Montalvá, Elena Sulleiro Igual, Ines Mercedes Oliveira Souto
Funding agency: Instituto de Salud Carlos III
Funding: 141000
Reference: CB21/13/00029
Duration: 01/01/2022 - 31/12/2022

Integración en el Servicio de Enfermedades Infecciosas

IP: Israel Molina Romero
Collaborators: Maria Luisa Aznar Ruiz de Alegria, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR21/00027
Duration: 26/05/2022 - 25/05/2026

Multicentre Controlled Open Randomized Clinical Trial to assess efficacy and safety of an anti-TB drug combination based on high dose Rifampicin, high dose Moxifloxacin and Linezolid for DS smear positive pulmonary TB during the first 8weeks of treatmen

IP: Adrián Sánchez Montalvá
Collaborators: Maria Luisa Aznar Ruiz de Alegria, Mª Teresa Tórtola Fernández
Funding agency: Instituto de Salud Carlos III
Funding: 187550
Reference: PI20/01378
Duration: 01/01/2021 - 30/06/2025

Related news

This new method improves and streamlines drug development processes

Members of the Infectious Diseases research group and the VHIR Management participated in the sessions and visited the areas where the CRESCER and FUTURO projects are developed.

The research, which is part of the CRESCER project in which Vall d'Hebron participates, has 1423 pregnant women among whom two different interventions will be tested.

Related professionals

Enric Domingo Ribas

Enric Domingo Ribas

Cardiovascular Diseases
Read more
Manuel Ramirez Valencia

Manuel Ramirez Valencia

Main researcher
Spine Research Unit
Read more
Immaculada Pérez Gladiador

Immaculada Pérez Gladiador

Administrative
Ethics Committees Support Unit (USCE)
Core Facilities Area
Read more
Ramona Vergés Capdevila

Ramona Vergés Capdevila

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.